A network-heuristic approach to improve the impact of genomic data on drug discovery

Abstract

The explosive growth of molecular diagnostic tests introduces the possibility of increasing our understanding of disease mechanisms in the clinic and promises to improve target identification for new therapies. A new paradigm is emerging in drug discovery that is driven by these clinically derived data. Unfortunately, the translation of novel insights into useful therapies remains costly and difficult. New clinical trial design and open validation of markers may reduce these barriers to clinical utility.